Trials / Completed
CompletedNCT01316432
PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients
A Study Assessing The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Subcutaneous Bolus And Subcutaneous Infusion Of Cenderitide In Patients With Chronic Heart Failure With Volume Overload (HF)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Nile Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cenderitide | Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion. |
| OTHER | Placebo | Placebo will be administered as a 24-hour SQ infusion |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2011-10-01
- Completion
- 2011-11-01
- First posted
- 2011-03-16
- Last updated
- 2012-10-18
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01316432. Inclusion in this directory is not an endorsement.